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Abstract
Background: Lymphoedema is a chronic condition that causes swelling in the body tissues. Presently, there is no
cure for lymphoedema; instead, current treatment is aimed at lifelong management to help control symptoms.
Intermittent pneumatic compression (IPC) therapy can be considered as an adjunct to standard lymphoedema
care; however, research regarding the efficacy of this treatment modality is limited.
Methods: Twenty participants were recruited from an outpatient lymphoedema clinic (South Wales, UK) to a
feasibility randomised control trial designed to evaluate the efficacy of an IPC device (LymphAssist, Huntleigh
Healthcare) in reducing lower limb volume. The primary objective was to assess feasibility in terms of (1) study feasibility,
including recruitment, retention and assessment of outcome measures, and (2) intervention feasibility, including
intervention fidelity and acceptability to participants. Participants were randomly assigned to a control group (n = 10)
or intervention group (n = 10). The control group received their standard lymphoedema care only for a 6-month
period, whereas the intervention group received their standard lymphoedema care plus an IPC device to use for
6 months. A bilateral lower limb assessment and quality of life survey were undertaken at baseline and 3- and 6-
month time points.
Results: The study recruited to target within the planned time frame with a retention rate of 80%. Issues relating
to potential recruitment bias and study attrition were identified and possible solutions explored. In addition,
supplementary primary outcome measures that are important to the study population were identified and will
be incorporated into the design of future studies.
Conclusion: This feasibility study identified that a larger randomised controlled trial investigating the efficacy
of home use IPC devices is feasible with modifications to the study protocol.
Trial registration: This trial is registered with clinicaltrials.gov (NCT03825263).
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Introduction
Lymphoedema is a chronic condition that causes swell-
ing in the body tissues due to an excess accumulation of
protein-rich fluid called lymph. This occurs as a result of
lymphatic failure which can be genetic in origin (primary
lymphoedema) or a consequence of damage to the lym-
phatics usually by trauma, inflammation and damage of
the lymph nodes (secondary lymphoedema) [1]. It can
affect any part of the body but usually occurs in the
arms or legs and has an estimated prevalence of between
2.29 and 3.59 cases per 1000 of the general population
in the UK [2].
Key characteristics of lymphoedema include an in-
crease in limb size and skin changes, as well as increased
limb heaviness and pain, which have negative sequelae
for both physical and psychosocial health [3]. Presently,
there is no cure for lymphoedema; instead, current treat-
ment is aimed at lifelong management to help control
symptoms. Such treatment is based on decongestive
lymphatic therapy (DLT) which is a combination of
manual lymph drainage (MLD), compression therapy,
exercises and skin care; this is accepted internationally
as the gold standard for successful lymphoedema man-
agement [4, 5].
Intermittent pneumatic compression (IPC) therapy
can be considered as an adjunct for DLT. IPC devices
consist of pneumatic cuffs that are incorporated into a
compression garment, which is connected to a pump
and applied to the limb. Multiple-chamber garments
typically provide sequential compression in an ascending
pattern up the limb. Pumps vary in timing cycles and
amount of pressure produced, ranging from low-
pressure, slow-inflation to high-pressure, rapid-inflation
devices [6].
Research regarding the efficacy of IPC is limited.
Whilst early studies suggested that MLD and IPC are
equally as effective in reducing upper limb oedema [7],
studies examining sequential IPC as a treatment for
lower limb lymphoedema [1, 6, 8, 9] demonstrated a lack
of consensus with regard to treatment parameters.
Historically, IPC pumps have used sequential cycles to
provide a peristaltic massaging effect along the limb
towards its root. This, however, does not mimic the
MLD process, which starts with the unaffected lymph
nodes and region of the body and moves proximally to
distally [10]. MLD is a specialised massage technique
that helps stimulate the lymphatic system and encour-
ages the flow of lymph fluid. However, it can be both
cost and time intensive for clinicians and patients alike,
and it is not always accessible due to an insufficient
number of trained therapists [11]. Newer IPC devices
have been designed to mimic MLD but have not yet
been evaluated in research studies. Furthermore, no
studies have examined IPC as a home treatment. Hence,
several aspects of IPC as a treatment for lymphoedema
require evaluation in the form of robust clinical research.
This feasibility study aimed to evaluate a proposed
methodology designed to assess the efficacy of IPC for
the treatment of lower limb lymphoedema. The study
methodology consisted of a pilot randomised control
trial of IPC plus standard lymphoedema care versus
standard lymphoedema care alone. Specific objectives
were to determine (1) study feasibility, including recruit-
ment, retention and assessment of outcome measures,
and (2) intervention feasibility, including intervention
fidelity and acceptability to participants.
Methods
Study design
This feasibility study was a non-blinded, randomised,
controlled trial (RCT). Ethical approval for this study
was obtained from the appropriate local NHS Research
Ethics Committee (LREC No 17/WA/0076) and registered
with ClinicalTrials.gov, NCT03825263 (https://clinical-
trials.gov/ct2/show/NCT03825263?term=IMPRESS&rank=
5). Study duration was 6 months for each participant, with
follow-up appointments at 3-month and 6-month time
points. This time frame was chosen as it fitted with the
routine appointments at the lymphoedema clinic where the
study was undertaken.
Participants
Preliminary screening was carried out by the clinical lead
of the outpatient lymphoedema clinic who notified the
study investigators of any eligible and willing patients. A
sample of twenty participants who met the study inclu-
sion and exclusion criteria (Fig. 1) and agreed to partici-
pate were recruited. All participants provided written
consent.
Outcome measures
As lymphoedema is defined by an increase in limb size,
the primary outcome measure used in this study was
change in limb volume. This parameter is universally
used in the assessment of lymphoedema treatments;
results would therefore allow comparison with existing
research/literature. Secondary outcomes included change
in quality of life scores according to the Quality of Life
Enjoyment and Satisfaction Questionnaire short form
(Q-LES-Q-SF) [12] and usability of the IPC device.
Baseline assessment
Following consent, each participant underwent a base-
line assessment to record the following parameters: age,
gender, height and weight (Table 1). Further information
about the type of lymphoedema and its stage according
to the International Society of Lymphology (ISL) staging
[5] as well as a brief medical history was obtained by
Dunn et al. Pilot and Feasibility Studies           (2019) 5:113 Page 2 of 9
Fig. 1 Inclusion and exclusion criteria
Table 1 Baseline demographics
Control (n = 10) Intervention (n = 10) All (n = 20)
Mean age (years) (SD) 41.3 ± 13.2 58.3 ± 11.5 49.8 ± 14.9
Gender (M to F) (%) 50:50 10:90 30:70
Weight (kg) (SD) 92.9 ± 29.2 95.5 ± 43.8 94.2 ± 36.2
Height (cm) (SD) 169.6 ± 8.5 162.9 ± 10.4 166 ± 9.8
BMI (SD) 30.2 ± 8.4 36.2 ± 12.2 33.2 ± 10.6
Lymphoedema stage
II 100% (10) 100% (10) 100% (20)
III 0% (0) 0% (0) 0% (0)
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reviewing the participants’ medical notes. Next, bilateral
limb assessment was undertaken which included leg vol-
ume measurement using a circumferential tape measure
method; a non-stretch tape measure (Medi, Germany)
was used to measure leg circumference at 40-mm inter-
vals from the top of the malleolus to a significant clinical
end point that was taken from the patient’s medical
notes. To assure consistent measurement, the same
registered nurse with experience in circumferential leg
measurements using a tape measure performed the
measurements, at baseline and at any follow-up appoint-
ments. The leg circumference measures were used to
calculate the volume of the 40-mm leg segments using
simple software (LymCalc V 4.0, UK) where leg volumes
are calculated by adding together segments [13]. Partici-
pants also completed the Quality of Life Enjoyment and
Satisfaction Questionnaire short form (Q-LES-Q-SF)
[12] at baseline, prior to being randomly assigned to the
control group (n = 10) or the intervention group (n = 10).
Randomisation
Participants were randomly assigned to the control or
intervention group via the use of sequentially numbered,
opaque, sealed envelopes. The envelopes were sealed by
an independent administrator and concealed from the
study investigator until recruitment, numbers one to ten
indicated the control group and 11 to 20 indicated the
intervention group. This simple method of randomisa-
tion creates a low risk of bias [14].
Control group
Participants in the control group received their standard
care for the 6-month study period. Standard prescribed
care within the lymphoedema clinic consisted of the four
components of DLT; however, it was recognised at the
study outset that this could potentially differ amongst
participants for a number of reasons. Firstly, the care is
largely self-administered with patients choosing whether
or not to implement the recommended components of
the treatment regimes. Secondly, the prescribed care can
vary; for example, some patients, although not all, are
prescribed MLD sessions with a trained therapist. In
order to capture this information, participants in the
control group were asked to complete weekly treatment
diaries which were returned when they attended their 3-
and 6-month reviews.
Intervention group
The intervention group received their standard care plus
an IPC device (LymphAssist, Huntleigh Healthcare)
(Fig. 2) to use for 6 months in addition to receiving their
standard lymphoedema care. The IPC devices operated
on a programme designed to mimic the MLD process,
first applying compression to the proximal aspect of the
limb before progressing distally. For safety purposes, the
devices were set to operate at a pressure of 40 mmHg
which is recommended by the device manufacturer for
home use of the device; this is low in comparison to the
pressures used in typical IPC devices which can reach
up to 120 mmHg. Each participant was given a demon-
stration by the study investigator on how to operate the
device at their clinic appointment, before trialling the
equipment themselves. Each device included an operat-
ing instruction manual, and participants were advised to
contact the study team if they had any issues or queries
related to using the device. Participants were instructed
to use the IPC device twice a day (preferably morning
and evening) for 35-min cycles (as recommended by the
device manufacturer). Diaries were also provided for the
intervention group to record their weekly treatment
Fig. 2 IPC device in use (LymphAssist, Huntleigh Healthcare)
Dunn et al. Pilot and Feasibility Studies           (2019) 5:113 Page 4 of 9
regimens and IPC device use. Participants in the inter-
vention group were also asked to complete a brief ques-
tionnaire that was designed to assess the usability of the
IPC device. The questionnaire involved the participants
rating the comfort, ease of use and practicality of the
device using a visual analogue scale and was completed
at 3- and 6-month time points.
Follow-up assessments
All baseline assessments including limb volume mea-
surements and quality of life surveys were repeated at 3-
and 6-month time points.
Results
Recruitment
The study recruited to target within the planned 6-week
time frame. A screening log was not completed so it was
not possible to gain information regarding patients who
were (i) ineligible or (ii) eligible to participate but de-
clined. Despite patients with stage III lymphoedema
being eligible to participate in the study, the study popu-
lation was made up exclusively of participants with stage
II lymphoedema.
Retention
The study achieved a retention rate of 80% of partici-
pants. Four participants withdrew from the study, three
at 3 months and one at 6 months (Table 2) (Fig. 3).
Three withdrew from the control group and one with-
drew from the intervention group after finding the IPC
device too uncomfortable to continue using.
Adherence to study protocol
Although participants were given a demonstration on
how to complete their weekly treatment diary at their
baseline visit and also had an instruction page to refer
to, completion of the diaries was found to be poor in
both the control and intervention group. Participants
were asked to estimate how many minutes they spent
each day on each of the four aspects of DLT and using
the IPC device (if applicable); however, this was infre-
quently done, with several participants giving a total
weekly estimate instead. Furthermore, missing diary data
was also problematic (control group, 37% at 3 months
and 42% at 6 months; intervention group, 20% at
3 months and 33% at 6 months).
Of the diaries returned by the intervention group, 75%
(6/8) reported using the IPC device twice daily as recom-
mended by the manufacturers at the 3-month review
point; this figure had decreased to 66% (4/6) by the 6-
month review.
Acceptability of intervention
The usability questionnaire showed good acceptance of
the study intervention; from the nine participants that
completed the IPC usability questionnaire, an average
score of 57/60 was returned at the 3-month time point
and 58/60 at the 6-month time point.
Outcomes measures
Anthropometric measures between the control and
intervention groups were similar; although there was a
greater proportion of females in the intervention group
than in the control group (90% vs 50% respectively)
(Table 1). The overall gender ratio of the study popula-
tion was male to female = 30:70; this reflects the normal
distribution of the condition which is more commonly
seen in females [15].
Both the control group and the intervention group
showed a decrease in mean limb volume at both 3- and
6-month time points (Table 3). Mean QOL scores
(according to Q-LES-Q-SF) in both the control and




The study recruited to target in a relatively short time
frame hence suggesting that recruitment to a larger
study of similar design would be attainable. However, it
was noted by the study investigator that most partici-
pants had stage II lymphoedema with well-controlled
symptoms and were highly concordant with the treat-
ment regimens prescribed by the clinic. According to
the ISL, lymphoedema stage II consists of limb swelling
which is not reduced by elevation, pitting may or may
not be present (if fibrosis is present); stage III lymphoe-
dema consists of hard tissue, increased skin folds, fat
deposits and warty overgrowths [5]. It is possible that
Table 2 Demographics of participants who completed the





Mean age (years) (SD) 52.1 ± 10.9 40.2 ± 25.3
Gender (M to F) (%) 20:60 10:10
Weight (kg) (SD) 97.2 ± 38.2 82.3 ± 28.4
Height (cm) (SD) 168.1 ± 10.6 164.2 ± 8.1
BMI (SD) 33.9 ± 10.9 30 ± 7.7
Lymphoedema stage
II 100% (16) 100% (4)
III 0% (0) 0% (0)
Randomisation group
Control 70% (7) 30% (3)
Intervention 90% (9) 10% (1)
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patients with stage III lymphoedema were excluded from
the study on account of them being more likely to have
severe skin problems or lower limb ulcers/wounds which
are contraindications to the use of IPC as specified by
the ISL [5]. Alternatively, recruitment bias is a possibility,
with the study being more likely to recruit patients who
were highly motivated to self-manage their condition and
as a result had a well-controlled lymphoedema status.
However, unfortunately, it was not possible to assess this
further as a screening log was not completed by clinic
Fig. 3 Participant flow
Table 3 Mean changes in affected limb volume
Time Period Control (ml) Intervention (ml) Difference in mean limb volume
change (control–intervention) (ml)
0–3 months − 360 95% CI [− 593, − 128] − 78, 95% CI [− 437, 279] − 282 (p = 0.13)*
0–6 months − 513 95% CI [− 1065, 39] − 530 95% CI [− 1100, 39] 17 (p = 0.56)*
3–6 months − 153 95% CI [− 667, 362] − 451 95% CI [− 1125, 223] 298 (p = 0.74)*
*P values from Mann-Whitney U test
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staff. This can perhaps be partly attributed to the fact that
the study was undertaken in a research naïve environ-
ment. Future studies undertaken in this setting would
therefore require a higher level of support for clinic staff.
It is vitally important to recognise and address recruit-
ment bias because it can significantly affect the integrity of
randomised controlled trials [16] with a reduction in
external validity hence meaning the results would not be
representative of the general lymphoedema population.
The current research aims to assess the efficacy of IPC
across both stage II and stage III lymphoedema; it is there-
fore paramount that this issue is addressed in future
planned studies. Strategies to ensure effective recruitment
could include designing a clear recruitment strategy prior
to study initiation, having more flexible participation
hours along with a less complex protocol. Allowing suffi-
cient time and staffing can also help minimise recruitment
bias [17].
Attrition is expected in most if not all clinical trials;
however, bias can be expected with the attrition rate
exceeds 20% [18]. The overall study attrition rate of 20%
(control group, 30%; intervention group, 10%) was there-
fore concerning. Attrition can undermine the internal
and external validity of a study, often resulting in biased
findings, especially if the participants are not lost at ran-
dom and have certain characteristics that could affect
the outcome. Analysis of the dataset did not reveal any
factors significantly associated with attrition in this
study. However, it is suspected that lack of interest, par-
ticularly from the control group, was a key contributing
factor to attrition in this feasibility study. Many of the
control group expressed their disappointment at being
not being allocated to receive the IPC device, and this
could have influenced their commitment to participation
and attendance at follow-up appointments. Additional
contributing factors, which are commonly cited in the
literature, could have included time restraints and
changes to daily life [19]. In order to try and address this
apparent apathy within the control group, it has been
decided that our next study will incorporate a cross over
design, where participants will act as their own controls
for the first 5 weeks of their participation before being
allocated an IPC device to use for the subsequent
5 weeks.
Issues associated with participant burden are often closely
associated with attrition. Study duration, intenseness and
invasiveness of the procedure all have an effect on the par-
ticipant and need to be considered when planning a larger
scale study [20]. The 6-month duration of this study was, in
retrospect, too long and probably represented a consider-
able source of participant burden. Although participants
needed to attend only three clinic appointments during this
time, they were still required to complete daily diaries and
use the IPC device twice daily (for those in the intervention
group). In order to try and address this issue, the timescale
of our next study will be based on the treatment lengths
seen in clinical practice. Typically, a lymphoedema patient
receiving manual lymphatic drainage from a therapist will
undergo therapy for around 3–4 weeks [11]; hence, it has
been decided that participants should receive the IPC inter-
vention for a similar time period. Reducing the length of
the treatment periods is intended to increase the likelihood
of the participant adhering to the treatment regime for the
treatment duration, which could have important implica-
tions for the results of future studies.
Data collection via the treatment diaries was adversely
affected by poor completion rates and lack of adherence
to the diary completion instructions. Although a cut-off
point has not been established in regards to missing
data, more than 10% can lead to a bias analysis [21]. In
addition to these problems, which according to the
literature are common-place, additional issues relating
to ‘back-filling’ of diary entries can also adversely affect
the quality and reliability of the data collected [22]. A
study by Stone et al. [22] found much better diary
completion compliance when using electronic diaries as
opposed to paper diaries (94% vs. 11% respectively);
however, other studies have not replicated this finding
[23]. Whilst financial limitations would rule out the use
of electronic diaries for our subsequent study, the paper
data collection diaries will be reviewed with a view to
simplifying them and making their completion less
onerous.
The primary outcome measure assessed within this
study was limb volume change. This study showed that
the IPC device had no effect on limb volume over the 6-
month period (as indicated by 95% confidence intervals);
however, it could be that the study was underpowered to
detect such an effect. Variation in standard lymphoe-
dema care across both the intervention group and
control group was noted; those participants receiving
MLD during the study duration typically displaying at
least temporary reductions in affected limb volume.
Similarly, one participant in the control group lost more
than 7 kg in weight during their participation in the
study as a result of being on a calorie-controlled diet
hence meaning that any reduction in limb volume could
be attributed to this. Such confounding factors will be
taken into consideration when undertaking a sample size
calculation for future studies.
Table 4 Mean quality of life scores ± SD
Control Intervention All
Baseline 50 ± 17 48 ± 7 49 ± 12
3months 51 ± 17 46 ± 11 48 ± 14
6months 49 ± 16 46 ± 7 47 ± 11
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Whilst volume change as a parameter was successfully
measured in this study, informal discussions with partic-
ipants revealed that other factors, such as perceived
‘limb heaviness’ and ‘tightness’, were equally or more
important to them when assessing improvements or de-
terioration of their condition. Hence, it was decided that
our subsequent study should include both objective and
subjective measures aimed at assessing such factors.
These parameters will be measured objectively using the
Myoton Pro, which works by recording damped natural
oscillation of soft biological tissue in the form of an
acceleration signal, providing outputs such as state of
tension, biomechanical and viscoelastic properties [24].
Participant perceived limb tightness and heaviness will be
also assessed subjectively via the use of visual analogue
scales.
The use of the Q-LES-Q-SF showed little or no changes
in scores at 3 months or 6months; it cannot be deter-
mined if this was a true representation of the participants’
quality of life or if the questionnaire used was not sensitive
enough to assess aspects of quality of life that specifically
relate to lymphoedema. In view of this, a questionnaire
that has been designed and validated for this purpose,
the Lymphoedema functioning, disability and Health
Questionnaire for Lower Limb Lymphoedema (Lymph-
ICF-LL), will be utilised for our subsequent study. The
questionnaire has five domains: physical function, men-
tal function, general tasks/household activities, mobility
activities and life domains/social life. These domains
were identified after a thorough literature review focus-
ing on problems in functioning related to the develop-
ment of lower limb lymphoedema [25].
Intervention feasibility
Assessment of intervention fidelity was hindered by the
poor rate of diary return. Available data suggest that use
of the IPC device as recommended by the manufacturers
was largely adhered to, although this decreased from the
three to 6-month time points, again suggesting issues
associated with participant burden. The acceptability
questionnaire demonstrated excellent acceptance of the
intervention across all three parameters of comfort, ease
of use and practicality.
Conclusion
This feasibility study has identified several important is-
sues that require consideration in the design of a larger-
scale randomised control trial which will investigate the
efficacy of IPC in the treatment of lymphoedema. Specific-
ally, potential issues relating to recruitment bias and study
attrition have been identified and possible solutions
explored. In addition, supplementary primary outcome
measures that are important to the study population have
been identified and will be incorporated into the design of
future studies. Whilst this feasibility study utilised a new
generation IPC device which operated on a programme
designed to mimic the MLD process (proximal to distal
compression), there is also a need to evaluate the efficacy
of the more commonly used, distal to proximal compres-
sion modes. Our planned future study will therefore
randomise participants to utilise the IPC device on one of
these compression modes for the intervention period of
the study.
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